Introduction {#s1}
============

Lung cancer is the leading cause of cancer death worldwide. Cigarette smoking is responsible for about 90% of lung cancers and decreases survival,[@pone.0001651-Bryant1] and yet the precise molecular alterations induced by smoking in lung that develop into cancer and impact survival have remained obscure. Using Affymetrix HG-U133A microarrays on 135 fresh frozen adenocarcinoma and paired non-tumor tissue samples from current, former and never smokers from the [E]{.ul}nvironment [A]{.ul}nd [G]{.ul}enetics in [L]{.ul}ung cancer [E]{.ul}tiology (EAGLE) study (<http://dceg.cancer.gov/eagle>), we sought to identify the genes that are altered by smoking in lung, and those, within the smoking signature, that have a role in lung carcinogenesis and outcome from lung cancer. We chose adenocarcinoma, the predominant histological subtype of lung cancer, because it occurs in subjects with no history of smoking as well as in smokers, providing a range of exposures ideal for the study of smoking-induced carcinogenesis. Specifically, in early stage adenocarcinoma tissue we compared gene expression from current (**C**) and never (**N**) smokers and identified the major genes using stringent criteria for gene selection (p\<0.001 and fold change \>1.5), the Benjamini-Hochberg procedure[@pone.0001651-Benjamini1] to calculate the False Discovery Rate (FDR), and Gene Ontology (GO)[@pone.0001651-Ashburner1] to classify the gene functional categories. We then verified whether the comparison between former (**F**) and never (**N**) smokers identified similar genes. We performed Gene Set Enrichment Analysis (GSEA)[@pone.0001651-Subramanian1] to identify common gene patterns where the single-gene analysis revealed only few overlapping genes. We further explored whether the genes that differentiated lung tumors of smokers from never smokers (**C/N** and **F/N**) also differentiated early stage tumor tissue (**T**) from paired non-tumor (**NT**) tissue to confirm the role of these genes in smoking-related lung carcinogenesis. We finally explored the impact of the smoking signature on survival from lung cancer in smokers. We validated **C/N** genes by Real Time-PCR in 68 samples used for the present microarray analysis, and confirmed them in 40 independent samples from EAGLE and a Mayo Clinic study of lung cancer.

Materials and Methods {#s2}
=====================

Study population and sample collection {#s2a}
--------------------------------------

This study included 105 subjects from EAGLE, a large population-based study of lung cancer conducted in the Lombardy region of Italy. EAGLE lung cancer cases were enrolled from the following 13 hospitals: A.O. Ospedale Niguarda Ca\' Granda, Milano; A.O. Spedali Civili, Brescia; Istituto Clinico Humanitas, Rozzano (MI); Ospedale di Circolo e Fondazione Macchi, Varese; Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milano; Istituto Scientifico Universitario Ospedale San Raffaele, Milano; A.O. Ospedale Luigi Sacco, Milano; A.O. San Paolo, Milano; A.O. Ospedale San Carlo Borromeo, Milano; IRCCS Policlinico San Matteo, Pavia; A.O. San Gerardo, Monza; A.O. Ospedale Fatebenefratelli, Milano; Ospedale San Giuseppe, Milano. The healthy controls in EAGLE were randomly selected from the same residential area of the lung cancer cases. After description of the EAGLE study by the study personnel, and discussion with potential participants, written informed consent was obtained under a protocol approved by the Institutional Review Board of each participating hospital and by the National Cancer Institute (Bethesda, MD). Subjects in this gene expression study, 44--79 years old, had histologically confirmed primary adenocarcinoma of the lung, stages I--IV, and provided detailed smoking and medical history information.

Overall, 180 adenocarcinoma and non-tumor tissue samples were selected for the analyses, including duplicate or triplicate samples from 14 subjects for quality control. Samples had been snap-frozen in liquid nitrogen within 20 minutes of surgical resection. A single pathologist confirmed the hospital-based diagnosis of adenocarcinoma, estimated the presence of malignant cells in each sample based on H&E-stained fresh frozen sections, and classified the samples as Tumor (**T**) and Non-Tumor (**NT**). From the original 180 samples, 148 provided sufficient quantity of high-quality RNA for microarray analyses; 13 additional samples were excluded because of technical problems. Normalization was conducted on the remaining 135 microarrays; corresponding CEL files and information conform to the MIAME guidelines are publicly available on the GEO database (accession number = GSE10072). After normalization, 13 samples were excluded because of low percentage of tumor cells in the tumor tissues. This report is based on 122 samples, of which 15 duplicates/triplicates were averaged, resulting in 107 final expression values from 58 tumor and 49 non-tumor tissues from 20 never smokers, 26 former smokers, and 28 current smokers. Quality assurance and distribution of cell types across smoking groups are described in [Appendix S1A, S1B, and S1C](#pone.0001651.s001){ref-type="supplementary-material"}.

Statistical analysis {#s2b}
--------------------

All statistical analyses were accomplished using R program language. Gene expression data were processed and normalized using Bioconductor Affy package, based on the Robust Multichip Average (RMA) method[@pone.0001651-Hochreiter1] for single-channel Affymetrix chips. All 22,283 probe sets based on RMA summary measure were used in class comparison analyses.

Average linkage hierarchical clustering of samples was based on one minus Pearson correlation as the dissimilarity metric.

An ANOVA analysis adjusting for sex was used to test whether genes were differentially expressed between smoking groups (**C/N** and **F/N**), between tumor tissue and non-tumor tissue (**T/NT**), or by pack years of cigarette smoking. Further analyses adjusted by tumor grade or excluding 6 subjects with emphysema or chronic bronchitis or 3 subjects who received chemotherapy prior to the study were conducted, with essentially unaltered results. For analyses including paired tissues (**T/NT** tissue samples from the same subjects), a linear mixed effects model was used to account for intra-person correlation.

To limit false positive findings, genes were considered statistically significant if their p-values were less than the stringent threshold of 0.001. Under the null hypothesis of no difference in expression profiles, and considering the analysis of 22,283 probes, we expect that by chance the average number of false positive findings will be ≤23. We used the Benjamini-Hochberg[@pone.0001651-Benjamini1] procedure to calculate the False Discovery Rate (FDR). We further restricted significant genes to those which showed at least 1.5 fold ratio of geometric means of expression between two groups. Gene selection based on p\<0.001 (two-sided) and fold-change \>1.5 are referred to as "stringent criteria".

The Cox Proportional Hazards model[@pone.0001651-Cox1] was used to estimate the effect of gene expression changes in **C/N** on survival from lung cancer in smokers. Of the 74 subjects included in this study (all stages), 34 (22 smokers) were alive, and 40 (32 smokers) were deceased as of May 2007. Among the deceased subjects, 36 died of lung cancer. The remaining 4 (2 smokers) died of other cancers and were censored at time of death in the analysis. The time from lung cancer to death or date of last follow-up was between 28 days and 5.0 years for the deceased subjects, and 3.7 and 5.7 years for the subjects alive in May 2007. The relative risk of gene expression was defined as the hazard ratio associated with one standard deviation change of the expression. Analyses were adjusted for stage, sex, and smoking. Age was similarly distributed across the groups and was not adjusted for in the analysis.

Analysis of total plasma cotinine concentration by gas chromatography/mass spectrometry {#s2c}
---------------------------------------------------------------------------------------

We verified the self-reported current smoking status by measuring plasma cotinine levels. The total cotinine (free plus cotinine *N*-glucuronide) concentration in plasma was quantified by GC/MS analysis using a method similar to that used for urinary cotinine,[@pone.0001651-Hecht1] with the addition of a solid phase extraction step carried out on an MCX column (Waters Corporation, Milford, MA).

One individual who reported to have quit smoking 2.6 years before the study had high cotinine levels (135 ng/ml) and was re-classified as a current smoker.

Gene Set Enrichment Analysis {#s2d}
----------------------------

Gene Set Enrichment Analysis (GSEA)[@pone.0001651-Subramanian1] was used to compare expression in groups of genes (gene-sets), between different tissues or between different comparison groups within the same tissue. GSEA analysis reveals a pattern of common gene-sets even when single-gene analysis reveals very few overlapping genes between groups. We modified the standard GSEA method by substituting an ANOVA test for the standard two-sample t-test to adjust for sex. Furthermore, we changed the permutation test for calculating the p-values by permuting residuals and using as weights the observed ANOVA coefficients divided by the standard error values. Up- and down-regulated genes were included in different gene-sets for the analyses.

Molecular function classification of smoking-altered genes {#s2e}
----------------------------------------------------------

Gene Ontology was used to assign the genes to functional categories.[@pone.0001651-Ashburner1] GoMiner[@pone.0001651-Zeeberg1] was utilized to rank-order the GO categories for the genes identified in the smoking comparisons.

Quantitative PCR validation and confirmation in independent samples {#s2f}
-------------------------------------------------------------------

We used quantitative real-time PCR (QRTPCR) to confirm the differential expression of 19 **C/N** selected genes (20 probes), including 14 genes from **T** and 5 from **NT** analyses. Primer and probe sets for the selected genes as well as control probes for GUSB and S18 (ABI) were run on 7500 Taqman under the manufacturer\'s standard protocol. Ct values were normalized based on GUSB expression.

Validation assays were performed in 68 samples used in the original microarray analyses, including 43 **T** (27 **C** and 16 **N** smokers), and 25 **NT** (18 **C** and 7 **N** smokers).

Confirmation assays were performed in 40 independent samples, including 19 **T** (12 **C** and 7 **N** smokers) and 21 **NT** samples (12 **C** and 9 **N** smokers). These samples were collected in EAGLE (10 **T** samples from 7 **C** and 3 **N** smokers, and 12 **NT** samples from 7 **C** and 5 **N** smokers-these samples were not used for the microarray analyses), and from the Mayo Clinic, Rochester, MN (9 **T** and 9 **NT** paired samples from 5 **C** and 4 **N** smokers).

Results {#s3}
=======

The molecular signature of cigarette smoking in lung adenocarcinoma {#s3a}
-------------------------------------------------------------------

To investigate the molecular changes associated with smoking in the tumor tissue, we compared gene expression changes between current and never (**C/N**) smokers ([Table 1](#pone-0001651-t001){ref-type="table"}). To avoid potential alteration of gene expression due to advanced tumor status, we limited smoking comparisons in tumor tissue to the early stages (stages I and II). Unless specified differently, "**T**" samples represent early stage adenocarcinomas. Results from the advanced tumor stage tissues are reported for completeness in [Appendix S2C](#pone.0001651.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0001651.t001

###### Number of probes and genes differentiating current from never smokers (C/N) and former from never smokers (F/N) in all tumor samples, early stage tumor samples (T), and all non-tumor (NT) tissue samples.

![](pone.0001651.t001){#pone-0001651-t001-1}

  Criteria for significance                           All stages Tumor   Stages I and II Tumor ("T")   Non-Tumor ("NT")                                             
  ------------------------------------- ------------ ------------------ ----------------------------- ------------------ ----- ----- ----- ---- ---- ----- ---- --- ---
  **p-value\<0.001**                     **Probes**         142                      119                      25          105   126   106   31   40   211   71   7   2
                                         **Genes**          119                      104                      22          97    104   89    25   35   191   64   7   2
  **p-value\<0.001+Fold change\>1.5**    **Probes**          61                      63                       17           3    98    64    26   4    75    28   1   0
                                         **Genes**           48                      56                       15           3    81    54    21   4    73    25   1   0

FDR = False Discovery Rate [@pone.0001651-Benjamini1]

Using stringent selection criteria (fold-change \>1.5 and p-value\<0.001), we identified 64 up- and 98 down-regulated probe-sets, representing 54 up- and 81 down-regulated genes ([Appendix S2A, S2B](#pone.0001651.s002){ref-type="supplementary-material"}). Most of the significantly up-regulated genes were involved in cell cycle/mitosis/cell division (e.g., TTK, CENPF, NEK2), while many of those down-regulated were involved in cell adhesion/cell cycle arrest (e.g., ADRB2, APLP2, MACF1), consistent with a role of these genes in neoplasia development.

The GoMiner results ([Appendix S2D](#pone.0001651.s002){ref-type="supplementary-material"}) confirmed that the mitosis genes (12 altered genes among the 127 mitotic genes on the HG-U133A chip, p\<0.001), and more generally those involved in cell cycle were the most commonly altered in the tumor tissue ([Table 2](#pone-0001651-t002){ref-type="table"}).

10.1371/journal.pone.0001651.t002

###### Cell cycle genes differentiating current from never smokers (C/N) in the early stage tumor (T) tissue samples, and corresponding values in the former/never smoker (F/N) and in the smokers\' paired tumor/non-tumor tissue (T/NT) comparisons.

![](pone.0001651.t002){#pone-0001651-t002-2}

  Probe ID                          Gene                      Chromosomal     Current/Never[†](#nt102){ref-type="table-fn"} N = 30   Former/Never N = 23   Tumor/Non-Tumor N = 36                  
  -------------- ------------------------------------------ ---------------- ------------------------------------------------------ --------------------- ------------------------ -------- ------ -----------
  204641_at        NEK2[\*](#nt103){ref-type="table-fn"}      1q32.2--q41                             3.45                                 0.0001                   2.84            0.0036   3.14   \<0.0001
  204822_at         TTK[\*](#nt103){ref-type="table-fn"}       6q13--q21                              3.27                                \<0.0001                  2.08            0.0123   2.22   \<0.0001
  218009_s\_at     PRC1[\*](#nt103){ref-type="table-fn"}        15q26.1                               2.99                                 0.0007                   2.61            0.0109   2.60   \<0.0001
  207828_s\_at     CENPF[\*](#nt103){ref-type="table-fn"}      1q32--q41                              2.88                                \<0.0001                  2.28            0.0034   2.77   \<0.0001
  202095_s\_at     BIRC5[\*](#nt103){ref-type="table-fn"}        17q25                                2.72                                 0.0002                   2.10            0.0145   2.55   \<0.0001
  203362_s\_at                     MAD2L1                         4q27                                2.67                                 0.0003                   1.93            0.0309   2.74   \<0.0001
  219918_s\_at                      ASPM                          1q31                                2.59                                 0.0008                   2.12            0.0218   2.87   \<0.0001
  210559_s\_at                      CDC2                        10q21.1                               2.54                                 0.0009                   2.02            0.0298   2.37   \<0.0001
  201897_s\_at                     CKS1B                         1q21.2                               2.36                                 0.0002                   1.89            0.0152   2.47   \<0.0001
  204170_s\_at                      CKS2                          9q22                                2.36                                 0.0006                   2.02            0.0148   1.69    0.0015
  222077_s\_at    RACGAP1[\*](#nt103){ref-type="table-fn"}      12q13.12                              2.35                                 0.0003                   1.91            0.0178   2.13   \<0.0001
  203214_x\_at                      CDC2                        10q21.1                               2.29                                 0.0006                   1.98            0.0150   2.12   \<0.0001
  219306_at        KIF15[\*](#nt103){ref-type="table-fn"}       3p21.31                               2.22                                 0.0002                   2.00            0.0047   1.90    0·0001
  209642_at        BUB1[\*](#nt103){ref-type="table-fn"}          2q14                                2.17                                 0.0009                   1.68            0.0507   2.02    0.0001
  210052_s\_at     TPX2[\*](#nt103){ref-type="table-fn"}        20q11.2                               2.06                                 0.0006                   1.87            0.0100   2.07   \<0.0001
  203418_at                        CCNA2                       4q25--q31                              1.99                                \<0.0001                  1.85            0.0012   1.82   \<0.0001
  212020_s\_at                     MKI67                       10q25-qter                             1.95                                \<0.0001                  1.71            0.0016   1.41    0.0006
  201088_at                        KPNA2                     17q23.1--q23.3                           1.82                                \<0.0001                  1.53            0.0079   2.34   \<0.0001
  211519_s\_at     KIF2C[\*](#nt103){ref-type="table-fn"}        1p34.1                               1.78                                 0.0004                   1.67            0.0062   1.51    0.0002
  218252_at                        CKAP2                         13q14                                1.75                                 0.0008                   1.52            0.0292   1.47    0.0001
  204887_s\_at                      PLK4                       4q27--q28                              1.74                                 0.0001                   1.55            0.0066   1.48   \<0.0001
  211080_s\_at     NEK2[\*](#nt103){ref-type="table-fn"}      1q32.2--q41                             1.57                                 0.0001                   1.50            0.0019   1.36    0.0002
  214894_x\_at                     MACF1                       1p32--p31                              0.65                                 0.0003                   0.64            0.0016   0.52   \<0.0001
  208634_s\_at                     MACF1                       1p32--p31                              0.60                                 0.0001                   0.58            0.0004   0.42   \<.0.0001
  202284_s\_at                     CDKN1A                        6p21.2                               0.54                                 0.0003                   0.70            0.0668   0.65    0.0082
  208893_s\_at                     DUSP6                       12q22--q23                             0.34                                 0.0003                   0.32            0.0012   0.84    0.3102

Probe selection restricted to estimates with p\<0.001 and fold-change \>1.5 or \<0.6667, and within the most inclusive category of genes with p≤0.001 in the GoMiner analysis (GO ID 7049, [Appendix S2D](#pone.0001651.s002){ref-type="supplementary-material"}).

Genes involved in the mitotic spindle formation. The double line separates up-regulated and down-regulated probes.

Lung cancer gene expression is similar in current and former smokers {#s3b}
--------------------------------------------------------------------

To verify whether the **C/N** smoking signature in the tumor was present also in former smokers, we compared the **C/N** and **F/N** signatures in **T** and found 26 probes (22 down- and 4 up-regulated, representing 21 genes) that differentiated both **C/N** and **F/N** using stringent selection criteria ([Appendix S2E](#pone.0001651.s002){ref-type="supplementary-material"}). Some of these genes, e.g., STOM, SSX2IP, TRPC6, APLP2 (2 probes), and DHRS7, exhibited a persistent alteration even in subjects (n = 6) who quit smoking more than 20 years before the study. The GSEA analysis showed that among the 64 up- and 98 down-regulated probes found in the **C/N** comparison in **T**, 58 and 90 probes, representing 50 up- and 73 down-regulated genes, were also up- and down-regulated, respectively in the **F/N** smoking comparison (p\<0.001, [Fig. 1](#pone-0001651-g001){ref-type="fig"}, and [Appendix S2F, S2G](#pone.0001651.s002){ref-type="supplementary-material"}). All cell cycle genes that differentiated **C/N** were also altered in **F/N**, although less prominently ([Table 2](#pone-0001651-t002){ref-type="table"}), indicating that alterations of these genes persist following smoking cessation. Importantly, the mitosis/cell cycle genes identified in **C/N** and **F/N** also differentiated the early stage tumor from the non-tumor tissue samples (**T/NT,** paired analysis) ([Table 2](#pone-0001651-t002){ref-type="table"}), while pack years of cigarette smoking, a composite index of intensity and duration that does not consider the time when smoking occurred, were not associated with gene expression in either **T** or **NT**.

![Comparison of gene expression differentiating current from never smokers (C/N) and gene expression differentiating former from never smokers (F/N) in early stage tumor tissue (T) using Gene Set Enrichment Analysis (GSEA).\
Left: Running Enrichment Score (y axis) is calculated by walking down the entire list of probes from Affymetrix HG-U133A chip (numbered from 1 to 22,283 in the x axis) ordered by the ANOVA coefficients divided by the standard error values from the Former/Never (F/N) smoking comparison. This running-sum statistic increases when a given probe is in the Current/Never (C/N) Gene Set of interest and decreases when the probe is not in the C/N Gene Set, with the magnitude of increment depending on the strength of the correlation between the probe and the F/N comparison. The Enrichment Score (ES) is the maximum deviation of the Running Enrichment Score from zero encountered in the random walk and reflects the degree to which the Gene Set is overrepresented at the extremes (top or bottom) of the entire ranked probe list. We report results for two different C/N Gene Sets: on the top, the 64 up-regulated probes, with ES = 0.87 and, on the bottom, the 98 down-regulated probes, with ES = −0.90. A leading edge subset of the Gene Set is defined as those probes in the Gene Set that appear in the probes ranked list at, or before, the point where the running sum reaches its maximum deviation from zero. The leading edge for the Gene Set of the C/N up-regulated probes contains 58 probes over 64 and the leading edge for the Gene Set of down-regulated probes contains 90 over 98 probes. This confirms that among the 64 up-regulated probes from the C/N comparison, 58 are also found in the F/N comparison; and among the 98 down-regulated probes from the C/N comparison, 90 are also found in the F/N comparison. Right: distributions of ES values created using a permutation procedure for (top) the Gene Set of up-regulated probes in C/N and (bottom) the Gene Set of down-regulated probes in C/N. These distributions are used to calculate the statistical significance (nominal p-value) of the observed ES values (p-value\<0.002 in both cases).](pone.0001651.g001){#pone-0001651-g001}

Smoking signature in the noninvolved lung tissue {#s3c}
------------------------------------------------

The **C/N** comparison in **NT** revealed 28 up- and 75 down-regulated probes, representing 25 up- and 73 down-regulated genes with the stringent selection criteria ([Table 1](#pone-0001651-t001){ref-type="table"}, and [Appendix S3A, S3B](#pone.0001651.s003){ref-type="supplementary-material"}). As expected, the CYP1B1 gene, known to be induced by smoking[@pone.0001651-Spira1], [@pone.0001651-Lampe1] was strongly up-regulated. The GoMiner results showed that the most smoking-altered genes were involved in cellular defense response (5 of 90 cellular defense genes on the chip, p\<0.001), and more generally in immune response ([Appendix S3C](#pone.0001651.s003){ref-type="supplementary-material"}).

MACF1, UBE21, and CBX7 (p\<0.001), and C16orf30 (p = 0.001) were shared between **T** and **NT** **C/N** comparisons. C16orf30 and UBE21, both on chromosome 16p13.3, are located within 246kb, but they do not appear to share specific transcriptional regulation mechanisms ([Appendix S4A](#pone.0001651.s004){ref-type="supplementary-material"}). The GSEA analysis revealed some similarities between **T** and **NT** in the overall pattern of smoking-induced alteration (p = 0.08 and 0.04, for up- and down-regulated genes, respectively, [Appendix S4B, S4C, and S4D](#pone.0001651.s004){ref-type="supplementary-material"}). Notably, NEK2 and TTK were among those similarly altered in both **T** and **NT** in the GSEA analysis. In contrast, the **F/N** comparison in **NT** showed no statistically significant genes ([Table 1](#pone-0001651-t001){ref-type="table"}), and was not further explored.

Smoking-associated gene expression signature and survival from lung cancer {#s3d}
--------------------------------------------------------------------------

We studied the overall gene expression signature of smoking in **T** and **NT** (98+64 **C/N** in **T**, 75+28 **C/N** in **NT**, minus 3 overlapping probes between **T** and **NT**, for a total of 262 probe-sets representing 230 genes) in relation to survival from adenocarcinoma in smokers (n = 54, [Appendix S5A](#pone.0001651.s005){ref-type="supplementary-material"}). Since only 262 probe-sets were included in this analysis, we used a less stringent criterion of p\<0.01 for gene selection ([Table 3](#pone-0001651-t003){ref-type="table"}). Altered expression in **NT** of genes involved in the mitotic spindle formation, e.g., NEK2 (p\<0.001) and TTK (p = 0.001) were associated with a 3-fold increased mortality risk ([Table 3](#pone-0001651-t003){ref-type="table"}, analysis adjusted for stage, sex, and smoking).

10.1371/journal.pone.0001651.t003

###### Mortality risk in smokers for gene expression differentiating current from never smokers (C/N) in lung tumor and non-tumor tissue samples (p\<0.01)

![](pone.0001651.t003){#pone-0001651-t003-3}

  Probe ID               Gene Symbol    p-value   RR[a](#nt104){ref-type="table-fn"}   95% CI[b](#nt105){ref-type="table-fn"} Lowest   95% CI[b](#nt105){ref-type="table-fn"} Highest   Tissue type[c](#nt106){ref-type="table-fn"}
  -------------------- --------------- --------- ------------------------------------ ----------------------------------------------- ------------------------------------------------ ---------------------------------------------
  **Increased risk**                                                                                                                                                                   
  204641_at                 NEK2        0.0008                   2.6                                        1.5                                             4.7                                             NT
  204822_at                  TTK        0.0011                   2.9                                        1.5                                             5.5                                             NT
  201292_at                 TOP2A       0.0041                   3.1                                        1.4                                             6.7                                             NT
  219306_at                 KIF15       0.0048                   2.8                                        1.4                                             5.9                                             NT
  218542_at                C10orf3      0.0068                   2.7                                        1.3                                             5.4                                             NT
  209642_at                 BUB1        0.0084                   2.8                                        1.3                                             5.9                                             NT
  201637_s\_at              FXR1        0.0007                   2.8                                        1.5                                             5.0                                              T
  213189_at             DKFZp667G2110   0.0088                   2.0                                        1.2                                             3.4                                              T
  **Decreased risk**                                                                                                                                                                   
  202068_s\_at              LDLR        0.0068                   0.5                                        0.3                                             0.8                                             NT
  214894_x\_at              MACF1       0.0091                   0.4                                        0.2                                             0.8                                             NT
  218804_at                TMEM16A      0.0095                   0.4                                        0.2                                             0.8                                             NT
  201651_s\_at             PACSIN2      0.0046                   0.4                                        0.2                                             0.8                                              T

Relative Risk of death. Analysis based on 54 current and former smokers using 262 probes from the Current/Never smoking comparisons (98 down- and 64 up-regulated probes from T and 75 down- and 28 up-regulated probes from NT, minus 3 overlapping probes in T and NT); models adjusted for tumor stage, sex, and smoking status

95% Confidence Interval

T = Lung adenocarcinoma samples of any stage (N = 42); NT = Non-Tumor tissue samples (N = 34)

Validation and confirmation of gene expression smoking signature {#s3e}
----------------------------------------------------------------

We selected 19 genes (20 probes) for validation by QRTPCR, including 14 genes for **T** and 5 for **NT** tissue, based on fold change (\>2) and cancer relevance.

Validation was based on 68 samples, including 43 **T** and 25 **NT**, also used for the microarray analysis. All 19 genes were up-regulated in the **C/N** comparison in these samples ([Table 4](#pone-0001651-t004){ref-type="table"}).

10.1371/journal.pone.0001651.t004

###### Quantitative Real-Time PCR validation of microarray results of genes differentiating current from never smokers (C/N) in tumor (T) and non-tumor (NT) tissue samples and confirmation in independent samples

![](pone.0001651.t004){#pone-0001651-t004-4}

  Gene Name                    ABI Assay ID    Average expression in validation samples[a](#nt107){ref-type="table-fn"}   Average expression in confirmation samples[b](#nt108){ref-type="table-fn"}                                   
  --------------------------- --------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------ ----------- ------- -------
  AURKA                        Hs00269212_m1                                    16.57                                                                       17.37                                         1.74        19.13     20.21   2.10
  BIRC5                        Hs00153353_m1                                    10.48                                                                       11.46                                         1.97        12.31     13.42   2.16
  BIRC5                        Hs00977611_g1                                    10.84                                                                       12.45                                         3.07        13.13     14.24   2.16
  CCNA2                        Hs00153138_m1                                    13.13                                                                       13.42                                         1.22        15.16     15.93   1.71
  CENPF                        Hs00193201_m1                                    11.23                                                                       12.87                                         3.13        12.89     13.00   1.08
  C10orf23                     Hs00216688_m1                                    11.78                                                                       12.58                                         1.74        13.72     14.74   2.03
  CKS1B                        Hs01029137_g1                                     9.36                                                                        9.91                                         1.46        11.19     11.69   1.41
  FOXM1                        Hs00153543_m1                                    10.43                                                                       11.65                                         2.33        12.25     12.92   1.60
  GGH                          Hs00608257_m1                                    11.92                                                                       13.75                                         3.55        14.79     15.70   1.88
  KIF20A                       Hs00194882_m1                                    12.40                                                                       13.65                                         2.38        15.26     15.76   1.41
  KIF4A                        Hs00602211_g1                                    12.42                                                                       13.66                                         2.37        14.64     15.82   2.27
  MKI67                        Hs00267195_m1                                    12.53                                                                       12.71                                         1.14        13.95     14.57   1.54
  NEK2                         Hs00601227_mH                                    12.61                                                                       14.52                                         3.74        15.91     18.01   4.27
  TPX2                         Hs00201616_m1                                    10.60                                                                       11.73                                         2.19        12.57     13.30   1.66
  TTK                          Hs00177412_m1                                    11.49                                                                       12.80                                         2.47        13.12     13.28   1.11
  **Non-Tumor Lung Tissue**     **N = 18**                                    **N = 7**                                                                                                                **N = 12**   **N = 9**          
  CEACAM5                      Hs00237075_m1                                    10.98                                                                       14.85                                        14.58        13.30     13.51   1.16
  CYBB                         Hs00166163_m1                                     5.86                                                                        8.19                                         5.03        8.20      9.30    2.15
  CYTL1                        Hs00184064_m1                                    11.54                                                                       14.61                                         8.36        14.16     14.09   0.96
  FGG                          Hs00241037_m1                                     9.05                                                                       11.99                                         7.71        11.03     15.36   20.13
  TM7SF4                       Hs00229255_m1                                    14.99                                                                       18.20                                         8.15        17.42     18.47   2.07

Validation in 68 samples used also for microarray analysis;

Confirmation in 40 independent samples from EAGLE and Mayo Clinic

C/N = Current/Never smoking comparison

Confirmation was based on 40 independent samples (19 **T** and 21 **NT**) from EAGLE (samples not used for microarray analysis) and the Mayo Clinic, Rochester, MN. All the 14 genes in **T** and 4 of 5 genes in **NT** were up-regulated by smoking also in the independent samples ([Table 4](#pone-0001651-t004){ref-type="table"}).

Discussion {#s4}
==========

In a population-based study with fresh frozen tissue samples of adenocarcinoma and noninvolved lung tissue (mostly paired samples), we identified a smoking signature that persists years after smoking cessation and is related to lung cancer development and survival.

Aneuploidy and chromosome instability are two of the most common abnormalities in cancer cells that arise through unequal segregation of chromosomes between daughter cells during mitosis. Thus, mitotic alterations are highly relevant for carcinogenesis. We found that smoking induces deregulation of this very mitotic process proceeding from lung tissue changes through cancer development to cancer death or survival. In fact, the smoking signature we identified comprises genes that regulate the mitotic spindle formation. These genes, such as NEK2[@pone.0001651-Petersen1], [@pone.0001651-Lou1] and CENPF[@pone.0001651-Petersen1] (both on 1q32-q41), TPX2[@pone.0001651-Gruss1], [@pone.0001651-Tonon1] and STK6 (or AURKA)[@pone.0001651-Kufer1] (related to the Aurora-A activation pathway important in tumor progression[@pone.0001651-Keen1]), TTK (linked to cell mitosis through EGFR,[@pone.0001651-Baonza1] a critical drug target for lung adenocarcinoma[@pone.0001651-Sharma1]), and BIRC5 (Survivin),[@pone.0001651-Goga1] have all been found over-expressed in smoking-related tumors. While previous studies have proposed these genes as targets for therapeutic interventions,[@pone.0001651-Keen1], [@pone.0001651-Sharma1]--[@pone.0001651-Perez1] our work suggests that they may be targets for chemoprevention in smokers as well. In fact, they were strongly induced by smoking in the early stage tumor tissue and some, e.g., NEK2 and TTK, were also associated with increased mortality risk. The latter finding was most evident in non-tumor tissue, likely reflecting the widely recognized field-cancerization effect by smoking,[@pone.0001651-Borczuk1] while in the tumor tissue, smoking-related genes\' effects on survival may be masked by extensive molecular alterations occurring during tumorigenesis.

In the non-tumor tissue, current smoking strongly altered immune response genes, consistent with the defense mechanisms of the lung tissue against the acute toxic effects of smoking. Among the gene most strongly down-regulated in **NT** was CX3CR1, located on chromosome 3p21.3, an area known to be often deleted in lung cancer,[@pone.0001651-Lerman1] particularly in smokers.[@pone.0001651-Wistuba1]

Current knowledge of gene expression altered by cigarette smoking is based on bronchoscopy-obtained airway epithelial cells or macrophages[@pone.0001651-Spira1], [@pone.0001651-Woodruff1]--[@pone.0001651-Harvey1] or peripheral leukocytes[@pone.0001651-Lampe1] from healthy smokers rather than directly on lung tissue. The few studies with lung tissue samples are very small[@pone.0001651-Powell1] or used RNA amplification[@pone.0001651-Miura1] or RNA pooling[@pone.0001651-Woenckhaus1] methods. Our results are consistent with some previous findings, such as smoking-related alteration of CYP1B1[@pone.0001651-Spira1], [@pone.0001651-Lampe1] or of the mitotic pathway in cancer survival.[@pone.0001651-Miura1] However, earlier studies were often limited by the small sample size, or lacked information on potential confounders, or availability of paired tumor and non-tumor lung tissue samples for the distinction of gene changes involved in lung carcinogenesis from those representing a transient smoking effect. We overcame these pitfalls with a relatively large sample size of fresh tumor and non-tumor lung tissues, detailed covariate information (e.g., sex, age, stage, previous lung diseases or chemotherapy), biochemical validation of the smoking status, and confirmation of the main findings in independent tissue samples.

In conclusion, our study provides clues on how cigarette smoking affects lung cancer development and survival. Functional assays to confirm these findings are warranted. If confirmed, these genes could become important targets for chemoprevention and treatment for lung cancer in smokers.
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